Lantern Pharma Inc. (LTRN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Lantern Pharma Inc. (LTRN) Healthcare & Pipeline Overview

Lantern Pharma Inc. is a clinical-stage biotechnology company employing AI and machine learning to streamline oncology drug development. Their AI platform, RADR, analyzes vast molecular data to identify promising drug candidates and optimize clinical trials, positioning them uniquely in the competitive biotechnology landscape with a focus on precision medicine.

What Is the Investment Thesis for LTRN?

Lantern Pharma presents a compelling investment thesis centered on its AI-driven approach to drug development, which has the potential to significantly reduce costs and timelines in the oncology space. The company's RADR platform offers a unique competitive advantage by enabling the identification of patient populations most likely to respond to specific therapies. The ongoing Phase II clinical trials for LP-100 in mCRPC represent a near-term catalyst. Successful trial outcomes, expected by late 2026, could lead to accelerated regulatory pathways and potential partnerships. Furthermore, the development of LP-300 and LP-184, along with the ADC program, diversifies the pipeline and offers multiple avenues for growth. However, the company's relatively small market capitalization of $29.2M and reliance on successful clinical trial outcomes pose significant risks.

Based on FMP financials and quantitative analysis

LTRN Key Highlights

LP-100 is in Phase II clinical trials for metastatic, castration-resistant prostate cancer (mCRPC), representing a near-term value inflection point.

• The RADR AI platform analyzes molecular data to identify patient populations most likely to respond to specific therapies, increasing the probability of clinical trial success.
• LP-300 is being developed as a combination therapy for non-small cell lung cancer adenocarcinoma in non-smokers or never-smokers, addressing a specific unmet medical need.
• The company's ADC program represents a strategic expansion into targeted cancer therapies, leveraging the growing market for antibody-drug conjugates.
• Lantern Pharma's AI-driven approach aims to reduce the high failure rates and costs associated with traditional drug development, improving capital efficiency.

Who Are LTRN's Competitors?

LTRN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LTRN's Key Strengths?

Proprietary AI platform (RADR).

• Pipeline of drug candidates.
• Expertise in AI and drug discovery.
• Focus on personalized medicine.

What Are LTRN's Weaknesses?

Limited financial resources.

• Reliance on successful clinical trial outcomes.
• Small market capitalization.
• Limited commercialization experience.

What Could Drive LTRN Stock Higher?

LTRN catalyst: Phase II clinical trial results for LP-100 in metastatic, castration-resistant prostate cancer (mCRPC) expected by late 2026.

• Development and advancement of LP-300 as a combination therapy for non-small cell lung cancer adenocarcinoma.
• Expansion of the RADR AI platform capabilities through incorporation of additional data sources.
• Potential strategic partnerships with pharmaceutical companies for co-development and commercialization.

What Are the Key Risks for LTRN?

Financial-distress signal — its Altman Z-Score of -21.93 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for LP-100, LP-300, or other drug candidates.
• Competition from larger pharmaceutical companies with more resources.
• Regulatory hurdles and delays in drug approval process.
• Limited financial resources and dependence on additional funding.
• Intellectual property challenges and patent disputes.

What Are the Growth Opportunities for LTRN?

• Expansion of the RADR platform: Lantern Pharma can expand the capabilities of its RADR platform by incorporating additional data sources, such as real-world evidence and patient-reported outcomes. This would enhance the platform's ability to identify predictive biomarkers and optimize clinical trial design. The market for AI-driven drug discovery is expected to grow significantly, presenting a substantial opportunity for Lantern Pharma to capture market share. Timeline: Ongoing.
• Strategic partnerships with pharmaceutical companies: Lantern Pharma can establish strategic partnerships with larger pharmaceutical companies to co-develop and commercialize its drug candidates. These partnerships would provide access to additional funding, expertise, and resources, accelerating the development and commercialization process. The pharmaceutical industry is increasingly seeking partnerships with innovative biotechnology companies, creating a favorable environment for Lantern Pharma. Timeline: Ongoing.
• Expansion into new therapeutic areas: While currently focused on oncology, Lantern Pharma can expand its AI-driven drug discovery platform into other therapeutic areas, such as autoimmune diseases and neurological disorders. This would diversify the company's pipeline and reduce its reliance on the oncology market. The market for AI in drug discovery is expanding across multiple therapeutic areas, presenting a significant growth opportunity for Lantern Pharma. Timeline: 2027-2028.
• Out-licensing of drug candidates: Lantern Pharma can out-license its drug candidates to other companies for further development and commercialization. This would generate upfront and milestone payments, providing additional funding for the company's research and development activities. The market for out-licensing drug candidates is robust, with numerous companies seeking to acquire promising assets. Timeline: Ongoing.
• Geographic expansion: Lantern Pharma can expand its operations into new geographic markets, such as Europe and Asia. This would provide access to a larger patient population and increase the company's revenue potential. The global biotechnology market is growing rapidly, presenting a significant opportunity for Lantern Pharma to expand its geographic reach. Timeline: 2028-2030.

What Are LTRN's Competitive Advantages?

• Proprietary AI platform (RADR).
• Extensive molecular data and genomic information.
• Pipeline of drug candidates in various stages of development.
• Expertise in AI and drug discovery.

What Does LTRN Do?

Lantern Pharma Inc., founded in 2013 and headquartered in Dallas, Texas, is a clinical-stage biotechnology company focused on transforming cancer drug discovery and development through the use of artificial intelligence (AI) and machine learning (ML). The company's core technology platform, RADR, leverages big data analytics and machine learning algorithms to analyze extensive molecular data, genomic information, and clinical trial results. This approach aims to identify patients most likely to respond to specific therapies, rescue failing drug candidates, and accelerate the overall drug development timeline. Lantern Pharma's pipeline includes several drug candidates in various stages of development. Their lead candidate, LP-100, is currently in Phase II clinical trials for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). LP-300 is being developed as a combination therapy for non-small cell lung cancer adenocarcinoma in non-smokers or never-smokers. Additionally, LP-184, a preclinical development drug candidate, is an alkylating agent designed to damage DNA in cancer cells that overexpress certain biomarkers or harbor mutations in DNA repair pathways. The company also has an ADC (antibody-drug conjugate) program focused on developing targeted cancer therapies. Lantern Pharma's AI-driven approach aims to reduce the high failure rates and costs associated with traditional drug development, ultimately bringing more effective and personalized cancer treatments to patients.

What Products and Services Does LTRN Offer?

• Develops AI-driven drug discovery platform (RADR).
• Identifies promising drug candidates using machine learning.
• Optimizes clinical trial design based on genomic data.
• Develops LP-100 for metastatic, castration-resistant prostate cancer.
• Develops LP-300 for non-small cell lung cancer adenocarcinoma.
• Develops LP-184 as an alkylating agent for cancer cells.
• Operates an ADC (antibody-drug conjugate) program.

How Does LTRN Make Money?

• Develops and out-licenses drug candidates.
• Generates revenue through strategic partnerships.
• Utilizes AI platform to reduce drug development costs.
• Focuses on personalized medicine approach.

What Industry Does LTRN Operate In?

The biotechnology industry is characterized by high risk and high reward, with significant investments required for research and development. The oncology segment is particularly competitive, with numerous companies vying to develop novel cancer therapies. Lantern Pharma's AI-driven approach differentiates it from traditional drug development companies by leveraging data analytics and machine learning to improve the efficiency and success rates of clinical trials. The market for AI in drug discovery is projected to reach $4 billion by 2027, reflecting the growing adoption of these technologies in the pharmaceutical industry.

Who Are LTRN's Key Customers?

• Patients with cancer.
• Pharmaceutical companies seeking drug candidates.
• Research institutions.
• Healthcare providers.

Company Profile

Lantern Pharma Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Dallas, US. The company is led by CEO Panna Sharma. LTRN has traded publicly since 2020.

Lantern Pharma Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -21.93 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Its free cash flow yield is -29.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.87 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -34.8%, the inverse of the P/E and a quick read on earnings relative to price.

LTRN Valuation & Market Position

With a $29.2M market cap, Lantern Pharma Inc. sits in the micro-cap segment of the market. Relative to its peer group, LTRN's quantitative score of 26/100 is below the peer average of 76/100.

Wall Street analysts project Lantern Pharma Inc. revenue of about $1.9M for fiscal 2026, with EPS near $-1.51.

LTRN Financials

LTRN Latest News

LTRN Analyst Consensus

LTRN MoonshotScore

Common Questions About LTRN (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources